Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.

J Virol. 2008 Jul;82(13):6678-88. doi: 10.1128/JVI.00352-08.

2.
3.

Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.

Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, Berkhout B, Sanders RW.

J Biol Chem. 2009 Sep 25;284(39):26941-50. doi: 10.1074/jbc.M109.004416.

5.

Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Champagne K, Shishido A, Root MJ.

J Biol Chem. 2009 Feb 6;284(6):3619-27. doi: 10.1074/jbc.M809269200.

7.

HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.

Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.

Biochim Biophys Acta. 2012 Dec;1818(12):2950-7. doi: 10.1016/j.bbamem.2012.07.020.

8.

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.

He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q.

Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16332-7. doi: 10.1073/pnas.0807335105.

9.

Origins of resistance to the HIVgp41 viral entry inhibitor T20.

McGillick BE, Balius TE, Mukherjee S, Rizzo RC.

Biochemistry. 2010 May 4;49(17):3575-92. doi: 10.1021/bi901915g.

10.

Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.

Menzo S, Castagna A, Monachetti A, Hasson H, Danise A, Carini E, Bagnarelli P, Lazzarin A, Clementi M.

New Microbiol. 2004 Apr;27(2 Suppl 1):51-61.

PMID:
15646065
11.
12.

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML.

J Virol. 2005 Oct;79(19):12447-54.

13.

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.

J Virol. 2006 Sep;80(17):8807-19.

14.

Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.

Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.

J Biol Chem. 2009 Feb 20;284(8):4914-20. doi: 10.1074/jbc.M807169200.

15.

Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).

Gonzalez E, Ballana E, Clotet B, Esté JA.

AIDS. 2011 Aug 24;25(13):1557-83. doi: 10.1097/QAD.0b013e328348a733.

PMID:
21572303
16.

The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.

Moseri A, Biron Z, Arshava B, Scherf T, Naider F, Anglister J.

FEBS J. 2015 Dec;282(24):4643-57. doi: 10.1111/febs.13541.

17.
18.

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.

Baatz F, Nijhuis M, Lemaire M, Riedijk M, Wensing AM, Servais JY, van Ham PM, Hoepelman AI, Koopmans PP, Sprenger HG, Devaux C, Schmit JC, Perez Bercoff D.

PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535.

19.

A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.

Pan C, Cai L, Lu H, Lu L, Jiang S.

J Biol Chem. 2011 Aug 12;286(32):28425-34. doi: 10.1074/jbc.M111.241992.

20.

Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.

Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scrivano L, Hoffmann C, von Laer D, Dittmar MT.

J Virol. 2005 Aug;79(16):10237-46.

Items per page

Supplemental Content

Support Center